ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Projecting the Impact and Costs of Near Point-of-Care Tuberculosis Screening Assays in Community-based Active Case Finding.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07420881 (Start 4 All - DARE-TB), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Start 4 All - DARE-TB
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCommunity-based active case finding (ACF) may reduce tuberculosis incidence and mortality but is not widely implemented due to resource constraints. How novel screening test characteristics would affect the impact and costs of ACF strategies is not clear.
methodsWe developed mathematical models of tuberculosis natural history and transmission, calibrated to data from 3 high tuberculosis burden countries (India, Vietnam, and the Philippines) and simulated the impact of annual community-based ACF programs. We compared annual screening, with or without an initial symptom screen, for 10 years with 2 hypothetical screening assays based on target product profile minimum targets: a low complexity (reaches 60% of the population) test with high sensitivity (90%) and moderate specificity (80%) costing $3; and a near point-of-care (reaches 80% of the population) test with moderate sensitivity (55%) and high specificity (98%) costing $2. We projected reductions in tuberculosis incidence, mortality, and costs under each scenario.
resultsAnnual screening with a low-complexity, high-sensitivity screening assay was projected to reduce tuberculosis mortality by 24%-38%, at an annual cost of $5.04-$5.83 per capita. Annual screening with a near-point-of-care, moderate-sensitivity assay was projected to achieve comparable reductions in mortality (24%-42%) at $3.49-$3.63 per capita. Symptom-based screening would yield more modest reductions in tuberculosis mortality (17%-24%) at an annual cost of around $1 per capita.
conclusionsNear point-of-care, moderate-sensitivity screening assays for tuberculosis could achieve substantial impact on tuberculosis mortality-equivalent to that of high-sensitivity assays and at lower cost-if they can be performed at scale in community settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.